AFFLUENT MEDICAL SA (AFME.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:AFME - FR0013333077 - Common Stock
AFME.PA Key Statistics, Chart & Performance
The current stock price of AFME.PA is 1.73 EUR. In the past month the price increased by 11.97%. In the past year, price increased by 23.13%.
AFME.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1EL.MI | ESSILORLUXOTTICA | 39.48 | 125.61B | ||
| ESL.DE | ESSILORLUXOTTICA | 39.42 | 125.42B | ||
| EL.PA | ESSILORLUXOTTICA | 39.29 | 125.00B | ||
| GBT.PA | GUERBET | 23.44 | 180.75M | ||
| ALCJ.PA | CROSSJECT | N/A | 113.75M | ||
| SVS.MI | SVAS BIOSANA SPA | 6.2 | 44.13M | ||
| PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 36.75M |
Related stock screener links
About AFME.PA
Company Profile
Affluent Medical SA provides treatments for serious and widespread diseases. The company is headquartered in Aix-En-Provence, Paca and currently employs 69 full-time employees. The company went IPO on 2021-06-14. The company designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. The company provides several products such as Kalios, Epygon, Artus. The company helps in treating heart disease and urinary incontinence. The firm provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.
Company Info
AFFLUENT MEDICAL SA
320 avenue Archimede, Les pleiades III Batiment B
Aix-en-Provence PACA FR
Employees: 66
Phone: 33442951220
AFFLUENT MEDICAL SA / AFME.PA FAQ
What does AFFLUENT MEDICAL SA do?
Affluent Medical SA provides treatments for serious and widespread diseases. The company is headquartered in Aix-En-Provence, Paca and currently employs 69 full-time employees. The company went IPO on 2021-06-14. The company designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. The company provides several products such as Kalios, Epygon, Artus. The company helps in treating heart disease and urinary incontinence. The firm provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.
What is the current price of AFME stock?
The current stock price of AFME.PA is 1.73 EUR. The price increased by 0.29% in the last trading session.
Does AFFLUENT MEDICAL SA pay dividends?
AFME.PA does not pay a dividend.
How is the ChartMill rating for AFFLUENT MEDICAL SA?
AFME.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of AFFLUENT MEDICAL SA (AFME.PA) based on its PE ratio?
AFFLUENT MEDICAL SA (AFME.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.38).
Can you provide the market cap for AFFLUENT MEDICAL SA?
AFFLUENT MEDICAL SA (AFME.PA) has a market capitalization of 68.08M EUR. This makes AFME.PA a Micro Cap stock.
AFME.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AFME.PA. When comparing the yearly performance of all stocks, AFME.PA is one of the better performing stocks in the market, outperforming 87.17% of all stocks.
AFME.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AFME.PA. AFME.PA may be in some trouble as it scores bad on both profitability and health.
AFME.PA Financial Highlights
Over the last trailing twelve months AFME.PA reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 29.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.57% | ||
| ROE | -70.19% | ||
| Debt/Equity | 1 |
AFME.PA Forecast & Estimates
10 analysts have analysed AFME.PA and the average price target is 3.72 EUR. This implies a price increase of 115.2% is expected in the next year compared to the current price of 1.73.